Elected representatives from Vermont make a symbolic gesture by buying Quebec products
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm'), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. Article content 'The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.' Article content Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib. Article content 'We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,' said Bertrand Ducrey, CEO of Debiopharm. 'We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.' Article content Continued Prioritization of RP-3467 and RP-1664 Article content Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025. Article content About Repare Therapeutics Inc. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content Debiopharm's Commitment to Patients Article content Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. Article content Forward-Looking Statements Article content This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of lunresertib to Debiopharm, including the potential benefits of the transaction and the achievement and receipt of milestone payments and royalties under the license agreement; the Company's anticipated cash runway; the timing, progress and results of the Company's ongoing Phase 1 LIONS and POLAR clinical trials; and the potential, tolerability, efficacy and clinical progress of the Company's product candidates, including the potential of lunresertib to treat patients with difficult-to-treat solid tumors as a monotherapy or in combination with Debio 0123. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at Article content Article content Article content Article content Article content Article content
CTV News
an hour ago
- CTV News
VIA Rail plans to use refurbished cars to improve service between Halifax-Montreal
A passenger section is seen during a tour of The Ocean passenger train at Halifax station in Halifax on Tuesday, July 15, 2025. Via Rail is marking 120 years of continuous service by The Ocean, making it the oldest named passenger train in Canada. THE CANADIAN PRESS/Darren Calabrese HALIFAX — The CEO of Via Rail says the Crown corporation wants to use refurbished rail cars to improve service between Halifax and Montreal. Mario Péloquin made the comments after a ceremony marking the completion of renovations to Via's Halifax station. Péloquin also noted that last year was the 120th anniversary of The Ocean — the train from Montreal to Halifax inaugurated in July 1904. The CEO says the federal government has committed to renewing the corporation's entire Canadian fleet within ten years. And in the interim, Péloquin says there are plans to refurbish stainless steel cars that are being retired in Central Canada for use in the Atlantic region. Mario Péloquin, president and CEO of Via Rail, speaks during a press conference at the company's Halifax station in Halifax on Tuesday, July 15, 2025. Via Rail is marking 120 years of continuous service by The Ocean, making it the oldest named passen... Mario Péloquin, president and CEO of Via Rail, speaks during a press conference at the company's Halifax station in Halifax on Tuesday, July 15, 2025. Via Rail is marking 120 years of continuous service by The Ocean, making it the oldest named passenger train in Canada. THE CANADIAN PRESS/Darren Calabrese But Péloquin says he doesn't know yet whether the refurbished cars will be enough to restore daily service to the Halifax-Montreal line, which currently runs three times a week. This report by The Canadian Press was first published July 15, 2025. The Canadian Press
CTV News
an hour ago
- CTV News
Montreal diners more demanding but better tippers than most of Canada: poll
A poll found that Montreal diners are most demanding in the country, but also that they tip the most. (Ryan Remiorz/The Canadian Press) A Montreal-based commerce software company wanted to better understand what people who go to restaurants expect and how that affects the tip they leave. In Montreal, expectations are high, and they hate rude service, but restaurant-goers from the island out-tip those from other provinces in Canada, according to Lightspeed Commerce's poll. 'Lightspeed's latest poll clearly shows that for Montreal diners, the experience is paramount,' said Lightspeed president J.D. Saint-Martin. 'They're not just looking for a meal; they're expecting professional, fast service in a clean environment. Restaurants that fail to deliver on these fundamental aspects risk losing a significant portion of their clientele.' Lightspeed's poll of around 7,000 diners found that Montrealers want fast and civil service in a clean spot. What bothers them most? Rude service: 37 per cent. Cold food: 29 per cent. Long wait for service: 27 per cent. Sticky tables or menus: 22 per cent. Lightspeed said it polled seven countries and five cities, and found that Montrealers were at the top of the list of those who said rude service was the most unbearable, so much so that nearly half will not return if service is not up to par. 'Rude servers took the lead in the reason for Montrealers to not return to a restaurant, with 48 per cent saying they would never return due to this,' the company said in a news release. 'Twenty-nine per cent said they have left a restaurant before being served due to slow service.' More demands, more tips However, for those servers that meet demanding Montreal diners' standards, they get rewarded, according to the poll. Over a third (35 per cent) of those polled said they are willing to tip between 15 and 20 per cent, compared with 29 per cent for the rest of the country. The majority of Canadians, the poll found, go between 10 and 15 per cent. Natacha Bianchet is a server at Brutopia Brewpub on Crescent Street in downtown Montreal. She serves a lot of tourists and does not agree that Montreal patrons out-tip other Canadians. 'I personally think that maybe Quebec doesn't have that big of a tipping culture, perhaps more of the European influence,' she said. 'When we get European tourists, they're not used to tipping, and I think that reflects in Quebec as well. For sure, Americans tip very well. It's ingrained that most of them would be an automatic 20 per cent.' Bianchet agrees that service should be fast and efficient and knows that to do the job well means more gratuity. However, this is not always the case. 'I do think it makes the job more stressful,' she said. 'For example, I know my service is good, and I know the people that I work with, all the service is great. I think also tipping comes down to personal preference, too, and at the end of the day, someone can tell you that your service was amazing and that they're coming back, but then still not tip well... You don't know what you're going to make at the end of the day. You don't know what you're going to make per month, but that's also part of the territory.' It should be noted that the minimum wage for servers in Quebec is $12.90, while it's $16.10 for non-tipped jobs. Bianchet hopes clientele realize that tipping is more complicated than just giving extra cash to a server who does a good job. 'If there's a $15 tip, not all $15 is going to me,' she said. 'It's much more nuanced than that, and I'm only getting a small percentage at the end of the day of that $15, and every bar and restaurant works differently. It's more complicated than they think it is, and it's not free money being handed to me, for sure. We're being taxed on it. Some places we share it, we split the tip, so yeah, at the end of the day, it's much less that the server is walking home with than they think we are.' The poll also found that 33 per cent of Montrealers are willing to pay more for their meal if tips are eliminated. The national average for that was 30 per cent. 'While Montrealers may be demanding in their attention to service, cleanliness and speed, they are clearly willing to reward the efforts of those that deliver,' said Saint-Martin. 'This suggests a genuine appreciation for excellent service, which is a powerful incentive for restaurants to invest in technology to empower their staff, giving them more time to focus on the customer experience.' Lightspeed's poll also found that half of diners are going solo (up from 43 per cent a year prior). The reason? Self care (47 per cent), enjoyment (43 per cent) and work lunches (24 per cent). 'Solo diners enjoy people watching (34 per cent) and finding a moment for some peace and quiet (34 per cent) equally. Thirty per cent are also interested in solo dining so they can try new menu items,' the company said.
